Our use of cookies

We use necessary cookies to make our site work. We’d also like to set optional analytics cookies to help us improve it. We won’t set optional cookies unless you enable them. Using this tool will set a cookie on your device to remember your preferences.

For more detailed information about the cookies we use, see Privacy & Cookies

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in a way that does not directly identify anyone.


Back to all News

Imperial Brands Subsidiary Submits Premarket Tobacco Applications for myblu Electronic Vaping Products

Imperial Brands subsidiary Fontem US LLC (Fontem US) today announced that it has submitted Premarket Tobacco Product Applications (PMTAs) to the U.S. Food and Drug Administration (FDA) seeking authorization for the continued marketing of a wide range of its myblu electronic vaping products.

Fontem US’s blu products play a fundamental role in the company’s goal of providing adult smokers with options that are potentially less harmful than combustible tobacco products.

The PMTA submissions include data from a comprehensive range of laboratory and clinical scientific studies, including product analyses, behavioral data, nonclinical health risk information, and information on the impact to both users and non-users of tobacco products.

Fontem US believes the evidence provided shows that blu electronic vaping products could play a role in the protection of the public health, in line with the guidance issued by FDA. Fontem US now awaits the FDA’s review of the applications and will provide additional information sought by the agency as part of the PMTA process.

“We agree that the electronic vaping industry should be held to the highest product and marketing standards while providing adult smokers with alternative products that could serve the interest of the public health,” said Antoine Blonde, president of Fontem US. “Fontem US looks forward to working with the FDA as the agency develops and enforces an evidence-based regulatory policy.”

Investor Contacts   Media Contacts  
Peter Durman +44 (0)7970 328 903 Alex Parsons +44 (0)7967 467 241
Matt Sharff +44 (0)7964 110 921 Simon Evans +44 (0)7967 467 684
James King +44 (0)7581 052 880